SEPN | Ticker Profile - Titan Protect

SEPN

Septerna, Inc.

Healthcare · Biotechnology · NGM

$31.15

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.3B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-11.20

Based on estimated future earnings — lower means cheaper

Rev Growth

+12,011.0%

Year-over-year revenue change

Profit Margin

-49.9%

How much profit the company keeps from each dollar of revenue

ROE

-9.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$43.00

+38% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 8 analysts covering this stock

About Septerna, Inc.

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

https://septerna.com

Country: United States Employees: 130 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.735

Good returns relative to risk taken

Kelly Fraction

0.0553

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.327

Drawdown risk outweighs the returns — higher risk profile

Annual Return

26.7%

Historical annualised return based on price data

Max Drawdown

-81.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

111

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$32.63

5% below the year high

52W Low

$9.11

242% above the year low

Avg Volume

316,660

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.5%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.80

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

6.10

Heavy leverage — higher financial risk if revenues decline

Current Ratio

4.71

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

4.63

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-50.1%

Profit from core operations before interest and tax

Free Cash Flow

$24M

Positive — the business generates more cash than it spends

Revenue (TTM)

$72M

Total revenue over the last 12 months

Net Income

$-36,040,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$60.00

Target Median

$43.00

Target Low

$35.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go